Kuano.ai, a software platform for rapid, cost-effective quantum modeling of enzymes, has raised £1 million in seed funding.
The investment from ACF Investors, o2h Ventures, and a syndicate of Cambridge-based angel investors will accelerate the company’s growth as it moves towards commercialization.
The funding will go towards expanding the technology team and the further development of Kuano’s platform and asset development, including its range of novel therapeutics.
Company: Kuano.ai
Raised: £1.0M
Round: Seed Round
Funding Month: July 2021
Lead Investors: ACF Investors and o2h Ventures
Additional Investors: a syndicate of Cambridge-based angel investors
Company Website: https://www.kuano.ai/
Software Category: a software platform for rapid>AI
About the Company: Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates. Kuano, is using its platform to advance its pipeline of novel therapeutics targeting unmet medical needs, as well as in collaborative programs with leading academic and commercial partners. This includes a recent research collaboration with Alzheimer’s Research UK University College London Drug Discovery Institute to identify inhibitors for treating degenerative neurological disorders.
Source: https://businesscloud.co.uk/kuano-raises-1m-in-seed-funding/